Newer Blood Thinner Brilinta Exceeds Plavix For Cardiac Bypass Surgery Patients

Newer Blood Thinner Brilinta Exceeds Plavix For Cardiac Bypass Surgery Patients.
In a trying out comparing two anti-clotting drugs, patients given Brilinta before cardiac detour surgery were less tenable to die than those given Plavix, researchers found. Both drugs ban platelets from clumping and forming clots, but Plavix, the more popular drug, has been linked to potentially threatening side effects in cancer patients.

In addition, some people don't metabolize it well, making it less effective. "We did meditate about a 50 percent reduction in mortality in these patients, who took Brilinta, but without any multiplication in bleeding complications," Dr Claes Held, an associate professor of cardiology at the Uppsala Clinical Research Center at Uppsala University in Sweden and the study's hero researcher, said during an afternoon host conference Tuesday.

So "Ticagrelor (Brilinta) in this setting, with acute coronary syndrome patients with the capacity need for bypass surgery, is more effective than clopidogrel (Plavix) in preventing cardiovascular and totality mortality without increasing the risk of bleeding". A danger with any anti-platelet medicament is the risk of uncontrolled bleeding, which is why these drugs are stopped before patients undergo surgery.

Held was scheduled to make known the results Tuesday at the American College of Cardiology's annual meeting in Atlanta. For the study, Held and colleagues looked at a subgroup of 1261 patients in the Platelet Inhibition and Patient Outcomes (PLATO) trial. The researchers found that 10,5 percent of the patients given Brilinta supplementary aspirin before surgery had a callousness attack, achievement or died from heart disease within a week after surgery. Among patients given Plavix with an increment of aspirin, 12,6 percent had the same adverse outcomes.

Patients taking Brilinta had a total number death rate of 4,6 percent, compared with 9,2 percent for patients taking Plavix. In addition, the cardiovascular decease rates were 4 percent among patients taking Brilinta and 7,5 percent amidst those taking Plavix. When Held's team looked at each group individually, they found no statistically significant idiosyncrasy for heart attack and stroke and no significant difference in major bleeding from the bypass operation itself. The two drugs employment in different ways.

New Blood Thinners Are Effective In Combination With Low Doses Of Aspirin

New Blood Thinners Are Effective In Combination With Low Doses Of Aspirin.
Brilinta, an theoretical anti-clotting medication currently awaiting US Food and Drug Administration approval, performed better than the vigour standard, Plavix, when utilized in tandem with low-dose aspirin, a inexperienced study finds. Heart patients who took Brilinta (ticagrelor) with low-dose aspirin (less than 300 milligrams) had fewer cardiovascular complications than those taking Plavix (clopidogrel) with the addition of low-dose aspirin, researchers found.

However, patients who took Brilinta with higher doses of aspirin (more than 300 milligrams) had worse outcomes than those who took Plavix with an increment of high-dose aspirin, the investigators reported. Antiplatelet drugs are in use to enjoin potentially dangerous blood clots from forming in patients with insightful coronary syndrome, including those who have had a heart attack. Brilinta has already been approved for use in many other countries.

In July 2010, an FDA panel voted 7-to-1 to second the use of Brilinta for US patients undergoing angioplasty or stenting to unrestrained blocked arteries, but the approval handle is still ongoing. The panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.